Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Danburstotug - ImmuneOncia Therapeutics

Next Previous
X
Search
Drug Profile

Danburstotug - ImmuneOncia Therapeutics

Alternative Names: IMC-001; STI-3031; STI-A1015

Latest Information Update: 20 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sorrento Therapeutics
  • Developer Asan Medical Center; ImmuneOncia Therapeutics; Sorrento Therapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - T-cell lymphoma

Highest Development Phases

  • Phase III Cervical cancer
  • Phase II Extranodal NK-T-cell lymphoma; Gastric cancer; Liver cancer; Oesophageal cancer
  • Phase I Malignant melanoma
  • No development reported Solid tumours

Most Recent Events

  • 13 Jun 2024 Updated efficacy, adverse events and pharmacokinetics data from a phase II trial in Extranodal NK-T-cell lymphoma presented at the 29th Congress of the European Haematology Association (EHA-2024)
  • 28 May 2024 No recent reports of development identified for phase-I development in Solid-tumours(Metastatic disease) in South Korea (Parenteral)
  • 15 Apr 2024 ImmuneOncia Therapeutics plans phase-II TMB-H trial for Solid tumours (Metastatic disease, Late-stage disease) in June 2024 (IV, infusion), (NCT06365840)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top